Rats exposed to hypobaric hypoxia were subsequently killed at 3 and 24 hours and at 3, 7, and 14 days (
n = 4 at each time point) after exposure, along with four control rats. They were anesthetized by intraperitoneal injection of 7% chloral hydrate and killed by transcardiac perfusion with a solution containing 2% paraformaldehyde in phosphate buffer (pH 7.4). The eyes were removed from the rats, immersed for 2 to 4 hours in the same fixative, and kept overnight in a solution of 15% sucrose in phosphate buffer. Frozen coronal sections of 40-μm thickness were cut with a cryotome (Frigocut; Leica, Wetzlar, Germany) and were processed by the avidin-biotin-peroxidase complex (ABC) technique to visualize VEGF, nNOS, eNOS, iNOS, GluR2/3, NMDAR1, OX-42, OX-18, and OX-6 immunoreactive sites. GluR2/3 antibody recognizes both GluR2 and GluR3 subunits of AMPA glutamate receptors. OX-42, -18, and -6 antibodies detect complement type 3 receptors (CR3 receptors), major histocompatibility class I and II (MHC I and -II) antigens, respectively, on the microglial cells. Sections were incubated for 30 minutes in phosphate-buffered saline (PBS; pH 7.4), containing 0.2% Triton X-100, and then separately with the antibodies at dilutions shown in
Table 2 , in PBS/Triton X-100 overnight at room temperature. After several washes with PBS/Triton X-100, the sections were incubated with biotinylated goat anti-rabbit immunoglobulin (Vector Laboratories, Burlingame, CA) for VEGF, GluR2/3, NMDAR1, and nNOS and with biotinylated goat anti-mouse immunoglobulin (Vector Laboratories) for eNOS, iNOS, OX-42, OX-18, and OX-6 for 1 hour. After washing, the sections were incubated with peroxidase-linked ABC (Vector Laboratories) for 90 minutes. The peroxidase activity was demonstrated by nickel-enhanced 3,3-diaminobenzidine (DAB; Sigma-Aldrich). Sections were counterstained by 0.5% methyl green nuclear stain for 10 minutes, dehydrated by immersion in alcohol and then cleared with xylene before mounting in medium (Permount; Fisher Scientific, Pittsburgh, PA). Some sections were treated simultaneously without the primary antibodies to confirm the specificity of immunoreactivities.